FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 295:1283-1286 December 2, 1976 Number 23 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

In homocystinuria due to cystathionine synthase deficiency thromboembolism is a major cause of mortality and morbidity. Recent studies by others identified an abnormally shortened platelet survival and increased platelet vacuolization in patients with homocystinuria. When we studied six additional patients, however, we found the platelet survival to be within normal limits for each. The mean survival (+/-1 S.D.) was 9.75+/-0.94 days (normal, 9.27+/-1.06). In addition, platelets from five patients with homocystinuria and three obligate heterozygotes could not be distinguished from those of seven normal control subjects by electron microscopy. Specifically, no increased vacuolization was observed. Genetic heterogeneity, technical differences of differences in plasma homocystine concentrations could account for these descrepant results. The mechanism of thrombosis in homocystinuria remains an open question.

This article has been cited by other articles:

• Mohan, I. V., Jagroop, I. A., Mikhailidis, D. P., Stansby, G. P. (2008). Homocysteine Activates Platelets In Vitro. CLIN APPL THROMB HEMOST 14: 8-18 [Abstract]  
• Monagle, P., Michelson, A. D., Bovill, E., Andrew, M. (2001). Antithrombotic Therapy in Children. Chest 119: 344S-370S [Full Text]  
• Thambyrajah, J, Townend, J.N (2000). Homocysteine and atherothrombosis--mechanisms for injury. Eur Heart J 21: 967-974